Improving quality of life in pancreatic cancer patients following high-intensity focused ultrasound (HIFU) in two European centers

Marinova, Milka; Feradova, H.; Gonzalez‐Carmona, Maria A.; Conrad, Rupert; Tonguc, Tolga; Thudium, Marcus; Becher, Marc Ulrich; Zhou, Kun; Gorchev, G; Томов, С; Strassburg, Christian P.; Attenberger, Ulrike; Schild, Hans H.; Dimitrov, Dobromir; Strunk, H.

doi:10.1007/s00330-020-07682-z

Cited by 25 publications

(22 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, in two different European centres (Germany and Bulgaria), not only pain relief but also improved physical, emotional and social parameters were reported for 80 pancreatic cancer patients treated with ultrasound-guided "thermal" HIFU. For these ultrasoundguided treatments, the JC TTS HIFU system was used allowing a 1 cm safety margin (parameters: Power = 100-400 W) [141]. Collectively, these studies showed the feasibility and safety of treating pancreatic cancer patients with HIFU.…”

Section: Treatment Of Pancreatic Cancer Patients With "Thermal" Hifumentioning

confidence: 97%

Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer

Mouratidis

Haar

2022

Cancers

View full text Add to dashboard Cite

Traditional oncological interventions have failed to improve survival for pancreatic cancer patients significantly. Novel treatment modalities able to release cancer-specific antigens, render immunologically “cold” pancreatic tumours “hot” and disrupt or reprogram the pancreatic tumour microenvironment are thus urgently needed. Therapeutic focused ultrasound exerts thermal and mechanical effects on tissue, killing cancer cells and inducing an anti-cancer immune response. The most important advances in therapeutic focused ultrasound use for initiation and augmentation of the cancer immunity cycle against pancreatic cancer are described. We provide a comprehensive review of the use of therapeutic focused ultrasound for the treatment of pancreatic cancer patients and describe recent studies that have shown an ultrasound-induced anti-cancer immune response in several tumour models. Published studies that have investigated the immunological effects of therapeutic focused ultrasound in pancreatic cancer are described. This article shows that therapeutic focused ultrasound has been deemed to be a safe technique for treating pancreatic cancer patients, providing pain relief and improving survival rates in pancreatic cancer patients. Promotion of an immune response in the clinic and sensitisation of tumours to the effects of immunotherapy in preclinical models of pancreatic cancer is shown, making it a promising candidate for use in the clinic.

show abstract

Section: Treatment Of Pancreatic Cancer Patients With "Thermal" Hifumentioning

confidence: 97%

Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer

Mouratidis

Haar

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…A large body of scientific precedence has demonstrated the significant benefit of HIFU in improving the quality of life for patients, with enhanced tumour control and reduced discomfort [ 166 , 167 ]. As a result, multiple clinical trials are being conducted, to investigate further the effect of HIFU on PC ( Table 4 ).…”

Section: Locoregional Therapiesmentioning

confidence: 99%

Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies

Bazeed

Day

Garg

2022

Cancers

View full text Add to dashboard Cite

Pancreatic cancer (PC) remains the seventh leading cause of cancer-related deaths worldwide and the third in the United States, making it one of the most lethal solid malignancies. Unfortunately, the symptoms of this disease are not very apparent despite an increasing incidence rate. Therefore, at the time of diagnosis, 45% of patients have already developed metastatic tumours. Due to the aggressive nature of the pancreatic tumours, local interventions are required in addition to first-line treatments. Locoregional interventions affect a specific area of the pancreas to minimize local tumour recurrence and reduce the side effects on surrounding healthy tissues. However, compared to the number of new studies on systemic therapy, very little research has been conducted on localised interventions for PC. To address this unbalanced focus and to shed light on the tremendous potentials of locoregional therapies, this work will provide a detailed discussion of various localised treatment strategies. Most importantly, to the best of our knowledge, the aspect of localised drug delivery systems used in PC was unprecedentedly discussed in this work. This review is meant for researchers and clinicians considering utilizing local therapy for the effective treatment of PC, providing a thorough guide on recent advancements in research and clinical trials toward locoregional interventions, together with the authors’ insight into their potential improvements.

show abstract

“…HIFU is regularly used in prostate cancer or in the management of uterine fibroids[ 77 , 78 ] but also in the management of PDAC, although it is much less common. HIFU has been suggested to improve quality of life and alleviate pain in patients with a metastatic course of their disease[ 79 ].…”

Section: Hifumentioning

confidence: 99%

Locoregional therapies and their effects on the tumoral microenvironment of pancreatic ductal adenocarcinoma

Lambin¹,

Lafon²,

Drainville³

et al. 2022

WJG

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second leading cause of death from cancer by 2030. Despite intensive research in the field of therapeutics, the 5-year overall survival is approximately 8%, with only 20% of patients eligible for surgery at the time of diagnosis. The tumoral microenvironment (TME) of the PDAC is one of the main causes for resistance to antitumoral treatments due to the presence of tumor vasculature, stroma, and a modified immune response. The TME of PDAC is characterized by high stiffness due to fibrosis, with hypo microvascular perfusion, along with an immunosuppressive environment that constitutes a barrier to effective antitumoral treatment. While systemic therapies often produce severe side effects that can alter patients’ quality of life, locoregional therapies have gained attention since their action is localized to the pancreas and can thus alleviate some of the barriers to effective antitumoral treatment due to their physical effects. Local hyperthermia using radiofrequency ablation and radiation therapy - most commonly using a local high single dose - are the two main modalities holding promise for clinical efficacy. Recently, irreversible electroporation and focused ultrasound-derived cavitation have gained increasing attention. To date, most of the data are limited to preclinical studies, but ongoing clinical trials may help better define the role of these locoregional therapies in the management of PDAC patients.

show abstract

Improving quality of life in pancreatic cancer patients following high-intensity focused ultrasound (HIFU) in two European centers

Cited by 25 publications

References 40 publications

Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer

Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer

Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies

Locoregional therapies and their effects on the tumoral microenvironment of pancreatic ductal adenocarcinoma

Contact Info

Product

Resources

About